Ke Ya-Ting, Kuo Chia-Chi
Ya-Ting Ke, RN, is a Head Nurse, Emergency Department, Chi-Mei Medical Center, Tainan, Taiwan; and Doctoral Student, School of Nursing, Kaohsiung Medical University, Kaohsiung, Taiwan. Chia-Chi Kuo, RN, is an Advanced Practice Nurse, Emergency Department, Chi-Mei Medical Center, Tainan, Taiwan; and Doctoral Candidate, School of Nursing, Kaohsiung Medical University, Kaohsiung, Taiwan; and Assistant Professor, Department of Nursing, Chang Jung Christian University, Tainan, Taiwan. Acknowledgments: This work was sponsored by grants from the Chi Mei Medical Center, Tainan, Taiwan (CMHCR10110). The authors thank Li-Chien Yang, Kuei-Ching Wang, and Ling-Ling Liang, the head nurses of the Center of Evidence-Based Medicine, Nursing Department, Chi Mei Medical Center, and Chia-Hui Tsai, the Clinical Instructor of the Department of Nursing, Tajen University, Pingtung County, Taiwan, for their dedication to evidence collection and critical appraisal. They also thank attending physicians, Drs Yin-Hsun Feng and Wei-Yu Chen, and the chemotherapy team of the Division of Hematology and Oncology, Chi Mei Medical Center, for their assistance in study recruitment. The authors have disclosed that they have no financial interests related to this article. Submitted December 18, 2014; accepted in revised form August 4, 2015.
Adv Skin Wound Care. 2017 Jan;30(1):27-34. doi: 10.1097/01.ASW.0000505611.28732.ba.
The common adverse effects associated with targeted therapy for cancer, such as epidermal growth factor receptor inhibitors (EGFRIs), are dermatologic toxicities that cause the patient physical discomfort and affect treatment. Colloidal oatmeal lotion (COL) has been proven to help prevent dermatitis and xerosis. Evidence of its effect on EGFRI-induced dermatologic toxicities, however, is limited. The purpose of this study was to explore the effect of COL on EGFRI-induced dermatologic toxicities.
This study used a 1-group pretest-posttest design with a convenience sample of 30 patients with cancer who developed EGFRI-induced dermatologic toxicities from a medical center in southern Taiwan. All participants applied topical COL 3 to 5 times a day for 4 consecutive weeks and received a pretest and 4 posttests.
A generalized estimating equation was used to assess the impact of demographics, disease characteristics, and weeks of COL use on dermatologic toxicity severity, body surface area affected, and level of pruritus.
Significant differences were found between the pretest and all posttests after using COL with regard to the severity, body surface area affected, and level of pruritus in participants who developed EGFRI-induced dermatologic toxicities (P < .05). There were no significant differences in demographics or disease characteristics on EGFRI-induced dermatologic toxicities.
Based on the study results, COL could improve the symptoms of dermatologic toxicities in those receiving EGFRIs with no adverse effects. Therefore, the authors suggest the use of COL in clinical settings.
癌症靶向治疗相关的常见不良反应，如表皮生长因子受体抑制剂（EGFRIs），是会导致患者身体不适并影响治疗的皮肤毒性。已证实胶态燕麦片洗剂（COL）有助于预防皮炎和皮肤干燥。然而，其对EGFRIs引起的皮肤毒性作用的证据有限。本研究的目的是探讨COL对EGFRIs引起的皮肤毒性的影响。
本研究采用单组前后测设计，便利抽样选取了30例来自台湾南部某医疗中心、发生EGFRIs引起的皮肤毒性的癌症患者。所有参与者每天外用COL 3至5次，连续使用4周，并接受一次前测和4次后测。
采用广义估计方程评估人口统计学特征、疾病特征和使用COL的周数对皮肤毒性严重程度、受影响的体表面积和瘙痒程度的影响。
在使用COL后，发生EGFRIs引起的皮肤毒性的参与者在前测与所有后测之间，在严重程度、受影响的体表面积和瘙痒程度方面均发现有显著差异（P <.05）。在EGFRIs引起的皮肤毒性方面，人口统计学特征或疾病特征没有显著差异。
基于研究结果，COL可以改善接受EGFRIs治疗者的皮肤毒性症状且无不良反应。因此，作者建议在临床环境中使用COL。
